Renal-cell carcinoma accounts for 2 percent of all cancers and a third of the patients who undergo resection of localized disease will have a recurrence. We report a case of a 58-year-old man with a right atrial mass protruding into right ventricle arising from the inferior vena cava, found by echocardiography, which was subsequently proved to be a recurrence of renal-cell carcinoma 25 years after radical left nephrectomy. This pattern of late recurrence is rare and suggests that this tumor's aggressive nature contributed to the degree of heart invasion and the patient's rapid death.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.echo.2006.05.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ethical dilemmas surrounding patients´ "unwise" treatment preferences and suboptimal decision quality: case series of three renal cell carcinoma patients who developed local recurrences after non-guideline-concordant care choices.
Pan Afr Med J
October 2024
College of Medicine, Qatar University, Doha, Qatar.
Patient engagement and shared decision-making (SDM) between patients and clinicians is the foundation of patient-centered care. It aims to reach a treatment option that fits the patient's preference and is guideline-concordant. We sought to evaluate the possible causes and outcomes of patient's non-guideline-concordant care choices.
View Article and Find Full Text PDFExoscopic-Endoscopic Resection of Intramedullary Spinal Cord Metastasis From Renal Cell Carcinoma With Ventral Exophytic Extension.
Cureus
December 2024
Department of Neurosurgery, Medical Research Institute Kitano Hospital, PIIF Tazuke-Kofukai, Osaka, JPN.
Intramedullary spinal cord metastasis (ISCM) is a rare manifestation of renal cell carcinoma (RCC). A 73-year-old man presented with left shoulder pain and left upper extremity weakness for two months. Magnetic resonance imaging (MRI) revealed intramedullary and intradural extramedullary lesions at the C5 level, compressing the spinal cord from the center of the cord and the left ventral side.
View Article and Find Full Text PDFCancer type-specific adverse events of immune checkpoint inhibitors: A systematic review and meta-analysis.
Heliyon
January 2025
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Background: The distribution of adverse events (AEs) triggered by immune checkpoint inhibitors (ICIs) across different cancer types has never been demonstrated.
Methods: Randomised controlled trials exclusively assessing ICI monotherapy in cohorts of over 100 patients were considered. Our primary outcome was a comprehensive summary of the distribution of all-grade treatment-related adverse events (TRAEs) as well as serious TRAEs (CTCAE grade 3 or higher) across different malignancies.
Right atrial metastasis after renal cell carcinoma operation: a case report.
AME Case Rep
January 2025
Department of Oncology, Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou, China.
Background: Treatment options for patients with high-risk metastatic clear cell renal cell carcinoma (mccRCC) include immune checkpoint inhibitors and tyrosine kinase inhibitors (TKIs), but clinical manifestations and treatment of these patients are rarely reported because patients with cardiac metastases and abrupt circulatory disorders are very rare and there are no precise guidelines to follow. In this study, we analyzed and discussed the clinical characteristics, related characteristics, pathogenesis and treatment strategies of patients with cardiac metastases of kidney cancer, so as to provide reference for the diagnosis and treatment of cardiac metastatic tumors.
Case Description: The patient was diagnosed with renal cell carcinoma and underwent surgical radical resection, no special treatment was performed after surgery.
EGR1 inhibits clear cell renal cell carcinoma proliferation and metastasis via the MAPK15 pathway.
Oncol Res
January 2025
Department of Urology, Shenzhen Longhua District Central Hospital, Shenzhen, 518110, China.
Background: Clear cell renal carcinoma (ccRCC), the leading histological subtype of RCC, lacks any targeted therapy options. Although some studies have shown that early growth response factor 1 (EGR1) has a significant role in cancer development and progression, its role and underlying mechanisms in ccRCC remain poorly understood.
Methods: The Cancer Genome Atlas (TCGA) database was utilized to examine the expression of EGR1 in ccRCC.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!